Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27898692 | 0.80 | KMT2A (0.60) | KMOMCL1P2RX7HTR2AHTR2C | |
| SCHEMBL1269116 | 0.79 | CDK4 (0.71) | CDK4CCND1 | |
| SCHEMBL419751 | 0.78 | KMO (0.57) | KMOMCL1P2RX7HTR2AHTR2C | |
| SCHEMBL7258387 | 0.78 | KMO (0.57) | KMOMCL1HTR7OXER1 | |
| SCHEMBL13345643 | 0.78 | KMO (0.56) | KMOMCL1HTR2AHTR2CCDK4 | |
| SCHEMBL19783673 | 0.78 | CDK4 (0.72) | CDK4CCND1 | |
| SCHEMBL30582936 | 0.78 | CDK4 (0.72) | CDK4CCND1 | |
| SCHEMBL10923807 | 0.78 | HTR7 (0.51) | KMOMCL1HTR7CDK4CCND1 | |
| SCHEMBL19149287 | 0.77 | HTR7 (0.50) | KMOMCL1P2RX7HTR2AHTR2C | |
| SCHEMBL9479598 | 0.76 | HDAC3 (0.59) | KMOOXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| WO-2006125621-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | REN, ACE, AGTR1 | KMO 1360/4885MCL1 4645/4885P2RX7 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.